CRISPR: Cell-based gene therapy for treatment of sickle cell disease
The FDA has approved the first cell-based gene therapy for treatment of sickle cell disease in patients 12 and older.
CRISPR can be directed to cut DNA in targeted areas, enabling the ability to accurately edit DNA where it has been cut.
Think of your DNA as an instruction manual for how your body works. Sometimes, there’s a typo in the manual that causes problems, like sickle cell disease. CRISPR is like a pair of tiny scissors and a GPS system combined. It can find the exact spot of the typo in the DNA and either fix it, remove it or replace it with the correct instructions. In CASGEVY gene therapy, physicians use CRISPR to repair or change these faulty instructions so that cells can work properly again.
How Do We Capture This:
This treatment is used for patients with recurrent vaso-occlusive crises or with a history of vaso-occlusive events.

Select the correct administration route – central or peripheral vein:

Section X codes are standalone codes. They are not supplemental codes. Section X codes fully represent the specific procedure described in the code title, and do not require any additional codes from other sections of ICD-10-PCS. When section X contains a code title which describes a specific new technology procedure, only that X code is reported for the procedure. There is no need to report a broader, non-specific code in another section of ICD-10-PCS. The X code captures the administration so no additional code is needed.
Capturing ICD-10-PCS codes for new technologies is under-captured. To ensure your coders are capturing new technologies, check to see if your EHR has the capability to FLAG these new technologies with an alert.
Sources:
- Cobb, B. (2024, October 2). New technologies eligible for add-on payment in CMS IPPS FY 2025. Medical Management Plus, Inc. https://www.mmplusinc.com/kb-articles/new-technologies-eligible-for-add-on-payment-in-cms-ipps-fy-2025 mmplusinc.com
- U.S. Food & Drug Administration. (2023, December 8). FDA approves first gene therapies to treat patients with sickle cell disease [Press release]. https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapies-treat-patients-sickle-cell-disease U.S. Food and Drug Administration
- U.S. Centers for Medicare & Medicaid Services. (2016). Using the ICD-10-PCS new technology section codes (ICD-10 documentation). https://www.cms.gov/Medicare/Coding/ICD10/Downloads/2016-Section-X-New-Technology-.pdf














